

9 JULY 2014, 16:00 AM CET

AMENDMENT TO THE PRESS RELEASE DISTRIBUTED ON 9 JULY AT 12H00 AM CET

AMENDMENT TO THE PRESS RELEASE DISTRIBUTED ON 9 JULY AT 12.00 CET

Cardio3 BioSciences has added that the transaction described in the release distributed on 9 July at 12h00 AM involved the sale of 141.800 shares at €43.5 each.

**Cardio3 BioSciences Announces Secondary Placement
With New Institutional Investors**

- **Six Swiss institutional funds purchase existing shares of the Company in a secondary placement**

Mont-Saint-Guibert, Belgium, - Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces the addition of six Swiss institutional funds to its shareholder base.

This transaction occurred aside of the market by exchange of shares between certain historical shareholders of the Company and Swiss professional investors. **The transaction involved the sale of 141,800 shares at €43.5 each.** The proportion of shares sold by the existing shareholders does not exceed 25% of their stake in the Company. The share capital and the number of shares of the Company remain unchanged after this secondary transaction.

Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: *"We are delighted to welcome new institutional funds to our shareholders. It reinforces our institutional shareholders base and has allowed us to manage to the benefit of all our shareholders the partial exit of some historical shareholders of the Company,"*

***** END *****

For more information contact:

Cardio3 BioSciences

Patrick Jeanmart, CFO

Anne Portzenheim, Communication Manager

www.c3bs.com

Tel : +32 10 39 41 00

aportzenheim@c3bs.com**Citigate Dewe Rogerson**

Chris Gardner

Tel : +44 (0) 207 638 9571



PRESS RELEASE - AMENDMENT

9 JULY 2014, 16:00 AM CET

AMENDMENT TO THE PRESS RELEASE DISTRIBUTED ON 9 JULY AT 12H00 AM CET

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure[®] is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure[®] consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath^{®_{ez}}, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.
